The DHX57 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated from the Raji B-lymphocyte line, providing a loss-of-function model for the DExH-box RNA helicase DHX57. This heterogeneous pool of edited cells enables population-level studies of DHX57-dependent processes and avoids clonal artifacts.
Raji is a continuous human B lymphoblastoid cell line derived from a Burkitt’s lymphoma patient, known for its EBV-positive status and mature B-cell characteristics, including antibody production and antigen presentation. Widely employed in immunology and oncology research, Raji cells offer a rapid proliferation rate and direct relevance to B-cell malignancies, making them an ideal host for gene knockout studies in lymphomagenesis.
DHX57 encodes a nucleolar DEAH-box RNA helicase that catalyzes ATP-dependent unwinding of structured RNAs during 60S ribosomal subunit biogenesis. It acts downstream of MYC and mTOR signaling, critical regulators of ribosome production and protein synthesis. DHX57 interacts with ribosomal proteins RPL5 and RPL11, nucleophosmin, and helicase DDX21 to process pre-rRNA intermediates. Disruption of DHX57 impedes 60S subunit maturation, reducing global translation and potentially impairing oncogenic proliferation.
In Raji cells, which frequently exhibit MYC-driven hyperproliferation, DHX57 knockout provides a relevant model to study the reliance of lymphoma cells on elevated ribosome biogenesis. Loss of DHX57 function is expected to compromise the translational machinery underlying sustained growth, offering a platform to test whether DHX57 ablation triggers apoptosis or growth arrest and whether it sensitizes cells to translational inhibitors, thus evaluating DHX57 as a therapeutic target in B-cell malignancies.
Typical applications include Western blotting and RT-qPCR for knockout validation, polysome profiling and rRNA processing assays to assess ribosome defects, and cell proliferation and apoptosis assays for functional phenotyping. The polyclonal population is suited for drug screens, synthetic lethality studies, and proteomic analyses of DHX57 interaction partners. For further information or to obtain this product, please contact Ascent Research.
